Clinical trial · Interventional
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma
NCT00375661CI-TRIAL-00019024completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatitis C, Chronic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| interferon-alfa-2b and ribavirin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- NO_INTERVENTION
- label
- interferon
- interventionNames
- Drug: interferon-alfa-2b and ribavirin
Primary outcomes (1)
- measure
- Incidence of adverse effect of interferon
- timeFrame
- During the treatment period
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of Hepatocellular carcinoma due to Chronic Hepatitis C Virus Infection. * Must be treated with curative treatment for primary tumor using either surgical resection or radiofrequency ablation therapy Exclusion Criteria: * No recurrence of hepatocellular carcinoma 3 months after the primary treatment * Renal dysfunction
References
Publications (0)
Data not yet available
No reference posted for this study.